MG
LRMR icon

Marex Group’s Larimar Therapeutics LRMR Stock Holding History

Marex Group’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$369K Sell
82,000
-230,000
-74% -$919K ﹤0.01% 710
2025
Q4 		$1.19M Buy
312,000
+171,000
+121% +$665K 0.01% 383
2025
Q3 		$455K Buy
+141,000
New +$529K ﹤0.01% 515

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Marex Group's LRMR Position: Q1 2026 in Review

Marex Group reduced its Larimar Therapeutics (LRMR) stake by 74% in Q1 2026, selling an estimated $919K and leaving 82,000 shares worth $369K. The position accounts for ﹤0.01% of the portfolio, ranked #710.

Marex Group first reported a position in LRMR in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.19M in Q4 2025. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Marex Group held 82,000 shares of Larimar Therapeutics worth $369K as of Q1 2026.
  • Marex Group sold 230,000 Larimar Therapeutics shares in Q1 2026, an estimated $919K.
  • Larimar Therapeutics made up ﹤0.01% of Marex Group's portfolio in Q1 2026, its #710 holding.
  • Marex Group first reported a position in Larimar Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Marex Group's Larimar Therapeutics position peaked at $1.19M in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.